Rimegepant sulfate hydrate|CAS 1374024-48-2|DC Chemicals

Cas No.:	1374024-48-2
Chemical Name:	Rimegepant sulfate hydrate
SMILES:	O=S(O)(O)=O.O=C1N(C2CCN(CC2)C(O[C@H]3C4=NC=CC=C4[C@H]([C@H](C5=C(C(F)=CC=C5)F)CC3)N)=O)C6=CC=CN=C6N1.O.[0.5].[1.5]
Formula:	C₂₈H₃₂F₂N₆O₃^.₁/₂H₂O₄S^.₃/₂H₂O
M.Wt:	610.26
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

Cat. No.	Product name	Field of application
DC72007	(3R,5R,6S)-Atogepant	(3R,5R,6S)-Atogepant ((3R,5R,6S)-MK-8031) is the enantiomer of Atogepant. Atogepant is a calcitonin gene-related peptide receptor (CGRP) antagonist. Atogepant can be used for researching migraine.
DC48154	SUN B8155	SUN B8155, a non-peptide agonist of calcitonin (CT) receptor, selectively mimics the biological actions of calcitonin. Calcitonin, a 32-amino acid peptide hormone secreted mainly from the thyroid gland, plays an important role in maintaining bone homeostasis.
DC47057	Vazegepant	Vazegepant is the first intranasal CGRP receptor antagonist for the study the acute research of migraine.
DC46162	Vazegepant hydrochloride	Vazegepant (BHV-3500) hydrochloride is a highly soluble CGRP receptor antagonist. Vazegepant hydrochloride is the first intranasal gepant for migraine. Vazegepant hydrochloride may be helpful in effective management of COVID-19 associated pulmonary inflammation.
DC9396	Olcegepant	Olcegepant(BIBN 4096; BIBN 4096BS) is the first potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor(IC50= 0.03 nM).
DC76506	Rimegepant sulfate hydrate	Rimegepant (sulfate hydrate) is an orally active, selective and competitive calcitonin gene-related peptide (CGRP) receptor antagonist with a Ki of 0.027 nM. Rimegepant (sulfate hydrate) can be used in migraine related research.
DC73391	BMS-694153	BMS-694153 is a potent, selective calcitonin gene-related peptide (CGRP) receptor antagonist with Ki of 0.013 nM for hCGRP (inhibition of 125I-CGRP binding in SK-N-MC cell membranes).
DC70404	FE 205030	FE 205030 (FE205030) is a potent, selective peptidic CGRP antagonist with IC50 of 0.2 nM.FE 205030 displays>100,000 fold against hAM1R and >6363 fold against hAM2R tested in Human CGRP, AM1R and AM2R receptor cAMP assays.FE 205030 inhibited CGRP-induced vasodilation in isolated human mesenteric resistance arteries in an ex vivo isometric myograph study; effectively blocked CGRP-induced vasodilation with a pA2 of 9.3.FE 205030 is a first in class injectable fast acting selective and potent agent for the treatment of acute episodic migraine.
DC70263	BMS-846372	BMS-846372 (BMS846372) is a potent, selective, orally active CGRP receptor antagonist with Ki of 0.07 nM (hCGRP).BMS-846372 inhibited CGRP-stimulated cAMP production in SK-N-MC cells with IC50 of 0.22 nM, could completely inhibited CGRP-mediated elevation of cAMP.BMS-846372 showed exposure-dependent inhibition of CGRP-induced increases in marmoset facial blood flow upon subcutaneous (sc) dosing in hαCGRP-induced increases in facial blood flow model.
DC48153	HTL22562	HTL22562 is a calcitonin gene-related peptide (CGRP) receptor antagonist for acute treatment of migraine.